Emerald Growth C holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
Emerald Growth Fund Class C HSPCX
- NAV / 1-Day Return 11.84 / +0.51 %
- Total Assets 1.4B
-
Adj. Expense Ratio
1.760%
- Expense Ratio 1.680%
- Distribution Fee Level Low
- Share Class Type Level Load
- Category Small Growth
- Investment Style Small Growth
- Min. Initial Investment 2,000
- Status Open
- TTM Yield 0.00
- Turnover 45%
USD | NAV as of Oct 02, 2026 | 1-Day Return as of Oct 02, 2026, 1:34 AM GMT+0
Morningstar’s Analysis HSPCX
Will HSPCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 21.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
F/m Emerald Life Sciences Innovation ETF | 6.13 | 91M | — |
U.S. Bank Money Market Deposit Account | 1.97 | 29M | Cash and Equivalents |
AAR Corp | 1.95 | 29M | Industrials |
InterDigital Inc | 1.83 | 27M | Technology |
Travere Therapeutics Inc Ordinary Shares | 1.68 | 25M | Healthcare |
VSE Corp | 1.68 | 25M | Industrials |
Mercury Systems Inc | 1.63 | 24M | Industrials |
Corcept Therapeutics Inc | 1.54 | 23M | Healthcare |
ESCO Technologies Inc | 1.51 | 22M | Technology |
Sensient Technologies Corp | 1.47 | 22M | Basic Materials |